Abstract
SARS-CoV-2 spreads predominantly through superspreading, with a minority of individuals responsible for the majority of transmission, though the drivers of this heterogeneity are unclear. Here, we assess the contribution of variation in viral load and daily contact rates to this heterogeneity by combining viral load and contact survey data in a mathematical model to estimate the secondary infection distribution. Using data from the BBC Pandemic and CoMix contact surveys, we estimate the basic reproduction number (R0 = 2.2, 95% CI 2.1-2.2) from first principles and the secondary infection distribution throughout the pandemic in the UK in 2020, and the effectiveness of frequent and pre-event rapid testing for reducing superspreading events. We find that individual heterogeneity in contacts – rather than individual heterogeneity in shedding – drives observed heterogeneity in the secondary infection distribution. Our results suggest that regular testing every 3 days, or pre-event testing with a minimum event size of 10, could reduce the mean reproduction number below 1 with moderate to high levels of uptake (60-80%) for pre-pandemic contact levels. This work demonstrates the potential for using viral load and contact data to predict heterogeneity in transmission and the effectiveness of rapid testing strategies for curbing transmission in future pandemics.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the Medical Research Council (MC_PC_19065 - WJE); European Commission (EpiPose 101003688 - KLMW, AG, WJE); NIHR (CV220-088 - COMIX; 16/137/109 - BJQ, 16/136/46 - BJQ); Bill & Melinda Gates Foundation (OPP1139859 - BJQ); Wellcome Trust (206250/Z/17/Z - AJK, LACC; WT098049AIA - SJDN); NIHR HPRU in Modelling & Health Economics (NIHR200908 - AJK, LACC); King's Together Rapid COVID-19 Call - SJDN, RPG; Huo Family Foundation Award - SP, SJDN.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used only openly available human data that were originally located at: https://zenodo.org/records/6542524 and https://github.com/adamkucharski/2020-cov-tracing/tree/master/data
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵5 These authors share first authorship
Correct the GitHub link to the code and data
Data Availability
All data used in the study are available online at https://github.com/bquilty25/superspreading_testing
